FDA warns India's Skyline Herbals after it ignored records requests for OTC drugs including toothpaste; all its drugs hit Import Alert 66-79.
What happened
Skyline Herbals was registered with FDA as a maker of over-the-counter drug products including toothpaste, using ingredients that can be swapped with diethylene glycol (DEG) or ethylene glycol (EG). Import records showed a shipment into the United States naming the firm as manufacturer, so FDA emailed a request for records on November 15, 2022, sent a second request on November 23, called the firm's US agent on December 2 (the agent said it no longer represented the firm), and sent a follow-up written request on December 3 that the shipper confirmed was delivered. The firm never responded and never provided the records, and FDA placed all its drugs on Import Alert 66-79 on January 5, 2023.
What FDA found
The firm refused to let FDA see or copy records that FDA is allowed to demand.
Section 301(e) of the FD&C Act, 21 U.S.C. 331(e)The firm did not answer FDA's written requests for records sent on November 15, November 23 and December 3, 2022.
Section 704(a)(4) of the FD&C Act, 21 U.S.C. 374(a)(4)Because the firm gave no records, FDA has no evidence of the quality assurance behind the drugs it says it makes, including products with ingredients at risk of DEG or EG contamination.
CGMP (current good manufacturing practice) requirements
What FDA wants
Respond in writing within 15 working days to CDER-OC-OMQ-Communications@fda.hhs.gov, marked with FEI 3017104669 and ATTN: Frank Wackes. The firm may supply information for FDA to consider or ask for an FDA inspection to be scheduled.
Who should pay attention
- brands and importers buying OTC drugs or toothpaste from this manufacturer
- US agents and distributors named on shipments from this firm
- companies sourcing high-risk ingredients such as glycerin or sorbitol from Indian suppliers
This is a summary. Read the original letter on fda.gov.